

Juha Punnonen, et al.
Application No: 10/828,559
Page 3

Attorney Docket No. 0344.210US

RECEIVED
CENTRAL FAX CENTER

JUL 11 2007

AMENDMENTS TO THE CLAIMS:

This listing of claims replaces all prior versions and listings of claims in the application:

1-138. (Canceled)

1 ~~139~~. (Currently Amended) An isolated or recombinant polypeptide comprising a polypeptide sequence that has at least ~~97%~~ 96% sequence identity to a polypeptide sequence comprising amino acid residues 81-265 of SEQ ID NO:4, wherein said isolated or recombinant polypeptide has an ability to induce an immune response against human epithelial cell adhesion molecule (EpCAM) or an antigenic fragment of human EpCAM.

2 ~~140~~. (Currently Amended) An isolated or recombinant ~~The polypeptide of claim 139, wherein the polypeptide comprises~~ comprising a polypeptide sequence that has at least ~~about~~ 97% 96% sequence identity to a polypeptide sequence comprising amino acid residues 24-265 of SEQ ID NO:4, wherein said polypeptide has an ability to induce an immune response against human epithelial cell adhesion molecule (EpCAM) or an antigenic fragment of human EpCAM.

3 ~~141~~. (Currently Amended) An isolated or recombinant ~~The polypeptide of claim 139, wherein the polypeptide comprises~~ comprising a polypeptide sequence that has at least ~~about~~ 96% sequence identity to the polypeptide sequence of SEQ ID NO:4, wherein said polypeptide has an ability to induce an immune response against human epithelial cell adhesion molecule (EpCAM) or an antigenic fragment of human EpCAM.

4 ~~142~~. (Currently Amended) The polypeptide of claim ~~139~~, wherein the polypeptide comprises a polypeptide sequence comprising amino acid residues 81-265 of SEQ ID NO:4.

5 ~~143~~. (Currently Amended) The polypeptide of claim ~~140~~, wherein the polypeptide comprises a polypeptide sequence comprising amino acid residues 24-265 of SEQ ID NO:4.

Juha Punnonen, et al.
Application No: 10/828,559
Page 4

Attorney Docket No. 0344.210US

⁶ 144. (Previously Presented) The polypeptide of claim ³ 141, wherein the polypeptide comprises the polypeptide sequence of SEQ ID NO:4.

⁷ 145. (Previously Presented) The polypeptide of claim ¹ 139, wherein the polypeptide has an ability to induce production of antibodies against human EpCAM or an antigenic fragment thereof.

⁸ 146. (Previously Presented) The polypeptide of claim ¹ 139, wherein the polypeptide induces a T cell response against human EpCAM.

⁹ 147. (Previously Presented) The polypeptide of claim ⁶ 146, wherein the polypeptide T cell proliferation response against human EpCAM.

¹⁰ 148. (Previously Presented) The polypeptide of claim ¹ 139, wherein the polypeptide induces production of at least one cytokine.

¹¹ 149. (Previously Presented) The polypeptide of claim ¹ 139, wherein the at least one cytokine is interferon-gamma.

¹² 150. (Previously Presented) The polypeptide of claim ¹ 139, wherein the polypeptide is glycosylated and/or pegylated.

¹³ 151. (Previously Presented) The polypeptide of claim ¹ 139, wherein the immune response comprises the production of antibodies that bind human EpCAM, proliferation of T cells, and production of one or more cytokines.

¹⁴ 152. (Previously Presented) The polypeptide of claim ² 140, wherein the polypeptide has an ability to induce production of antibodies against human EpCAM or an antigenic fragment thereof.

Juha Punnonen, et al.
Application No: 10/828,559
Page 5

Attorney Docket No. 0344.210US

¹⁵
~~153~~. (Previously Presented) The polypeptide of claim ~~140~~², wherein the polypeptide induces a T cell response against human EpCAM.

¹⁶
~~154~~. (Previously Presented) The polypeptide of claim ~~140~~², wherein the polypeptide induces production of at least one cytokine.

¹⁷
~~155~~. (Previously Presented) The polypeptide of claim ~~140~~², wherein the immune response comprises the production of antibodies that bind human EpCAM, proliferation of T cells, and production of one or more cytokines.

¹⁸
~~156~~. (Previously Presented) The polypeptide of claim ~~141~~³, wherein the immune response comprises at least one of an ability to induce production of antibodies against human EpCAM or an antigenic fragment thereof, induce a T cell response against human EpCAM, or induce production of at least one cytokine.

¹⁹
~~157~~. (Previously Presented) A composition comprising the polypeptide of claim ~~139~~¹ and a carrier, diluent, or excipient.

²⁰
~~158~~. (Previously Presented) The composition of claim ~~157~~¹⁹, wherein the composition further comprises at least one adjuvant, immunomodulatory polypeptide, or cytokine, or any combination thereof.

²¹
~~159~~. (New) The polypeptide of claim ~~139~~¹, wherein the polypeptide comprises a polypeptide sequence that has at least 98% sequence identity to a polypeptide sequence comprising amino acid residues 81-265 of SEQ ID NO:4.

²²
~~160~~. (New) The polypeptide of claim ~~140~~², wherein the polypeptide comprises a polypeptide sequence that has at least 98% sequence identity to a polypeptide sequence comprising amino acid residues 24-265 of SEQ ID NO:4.

Juha Punnonen, et al.
Application No: 10/828,559
Page 6

Attorney Docket No. 0344.210US

²³
~~161~~. (New) The polypeptide of claim ~~141~~³, wherein the polypeptide comprises a polypeptide sequence that has at least 97% sequence identity to the polypeptide sequence of SEQ ID NO:4.

²⁴
~~162~~. (New) The polypeptide of claim ~~161~~²³, wherein the polypeptide comprises a polypeptide sequence that has at least 98% sequence identity to the polypeptide sequence of SEQ ID NO:4.

²⁵
~~163~~. (New) A method of inducing an immune response against human EpCAM or an antigenic fragment thereof in a subject, comprising administering to the subject an effective amount of the polypeptide of claim ~~139~~¹.

²⁶
~~164~~. (New) A method of inducing an immune response against human EpCAM or an antigenic fragment thereof in a subject, comprising administering to the subject an effective amount of the polypeptide of claim ~~140~~².

²⁷
~~165~~. (New) A method of inducing an immune response against human EpCAM or an antigenic fragment thereof in a subject, comprising administering to the subject an effective amount of the polypeptide of claim ~~141~~³.

166. (New) A nucleic acid that encodes the polypeptide of claim 139.

167. (New) A nucleic acid that encodes the polypeptide of claim 140.

168. (New) A nucleic acid that encodes the polypeptide of claim 141.